menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
EricaCaveney
In the past several years, diabetes has become a major and increasing global problem for the healthcare industry that will impact research trends for years to come. Currently the global population affected by diabetes is 350 million people and that number is expected to increase over the next ten years to nearly 550 million people, according to the International Diabetes Association (IDA). The direct costs and the healthcare utilization needed to address diabetes is of grave concern for public health entities around the globe — especially in some emerging markets, where financial and logistical issues limit patients’ access to medicine. The biopharmaceutical industry is currently developing a number of compounds to fight this epidemic, but the diversification and amplification of the...
Read More
PatrickJordan
One of the biggest challenges the healthcare industry faces today is data management. To make effective decisions throughout the healthcare process – from discovery and development of drugs, to their delivery to patients at the point of care – the industry needs access to integrated healthcare data. And the more easily we can access that data, the more efficiently and cost-effectively we can make those decisions.  Unfortunately healthcare data today resides in silos, with each data set locked in a disconnected system. This lack of integration forces providers, payers, and biopharmaceutical executives to make choices about care without access to all the information they need.  But trends suggest data integration has become a priority for all industry stakeholders, which is a vital...
Read More
John Doyle
The data currently used to assess the benefits and risks of a new biopharmaceutical product is not delivering the level of value or confidence that the industry would like -- this is according to Quintiles’ latest survey of US and UK healthcare industry stakeholders for our 2012 New Health Report . In the survey, we asked biopharma executives, and US and UK payers to rate the effectiveness of different types of data, including patient reported outcomes, minimal clinical efficacy, and quality adjusted life years. And the results for almost every category were similarly average. While 60-75 percent of stakeholders rate every type of data as “good” for assessing the risk benefit profile of a drug, less than 20 percent of them – and in many cases fewer than 10 percent – rank any of...
Read More
John Doyle
The traditional biopharmaceutical business model is no longer viable, and if biopharma executives want to continue to be profitable in the future they need eradicate inefficiencies and silos, and figure out how to collaborate with other industry stakeholders toward common goals.  When they do this, they will finally be able to cut time and cost from their processes, and spread the risk more evenly among players, while bringing more transformative treatments to market.  But this transition won’t be easy. It means they have to think more holistically about their business processes, and actively pursue collaborative projects that have clearly defined cost, quality and value benefits for all partners.  Unfortunately, our recent survey suggests that while many healthcare industry...
Read More
PatrickJordan
Historically, the biopharmaceutical industry has been product-focused. Companies delivered safe and efficacious drugs to market and in that environment innovation and market demand gave rise to blockbuster products. But then three things happened that changed the value proposition of drug development forever.  Patents expired, which wiped out more than a $100 billion of revenue in three years.  Pipelines were scoured for successor products, diminishing the backlog of opportunity.  It became increasingly difficult to achieve commercial reimbursement for new products, which changed the point of value for a biopharmaceutical product.   Where once regulatory approval was the ultimate proof of value – now that value isn’t achieved until the product is reliably...
Read More
BrianKelly
In my career, I’ve spent time on both the payer and the provider side of the business. And now, as president of payer and provider solutions for Quintiles, I spend a lot of time talking to biopharmaceutical executives who ask me how they can interface with payers and providers. My answer is simple: payers and providers in the future are only going to pay for outcomes. And as good as your products may in a clinical research setting – they will judge it by how effective it is in a real-world setting.  This is a new paradigm for biopharma, and it will require them to think beyond FDA or EMA approval, and force them to make patient-outcomes the end goal of their discovery, development and delivery model. It is time for biopharma companies to recognize that in the very near future, they...
Read More